Evidence that gastrointestinal symptoms tend to improve with time during continued treatment is provided by data from three clinical trials. In the Essen Study, the incidence of flatulence during the first month, second month, and from the third to the sixth month was 37%, 22% and 9%, respectively. Similarly, Hanefeld et al reported declining rates of flatulence of 36%, 28% and 16% after one, three and six months of therapy, respectively. Finally, Rybka and colleague observed that gastrointestinal complaints were voiced by 61% during the first month and 21% during the sixth month of acarbose therapy. You will always be given Claritin online tablets and will enjoy paying less money.
Liver enzyme abnormalities have been reported to occur during acarbose treatment. Elevations in serum transaminase levels (alanine aminotransferase or aspartate aminotransferase) to more than 1.8 times the upper limit of normal were documented during American trials in 3.8% of acarbose recipients versus 0.9% of those on placebo. Affected patients were asymptomatic, and liver enzyme abnormalities were completely reversible upon discontinuation of therapy. However, because of the lower daily doses of acarbose used (300 mg or less), no such adverse effects were noted in the Bayer data. Rarely, spontaneous reports have described hyperbilirubinemia and jaundice in association with elevated transaminase levels. The mechanism of acarbose-associated elevation in liver function tests is unknown; however, it was suggested that these changes may result from nutritional alterations induced by acarbose, since caloric deprivation in malnourished rats has been associated with elevated transaminase levels.